
Cancer Epidemiology Biomarkers & Prevention Vol. 9, 905-910, September 2000
© 2000 American Association for Cancer Research
N-Acetyltransferase-2 Genetic Polymorphism, Well-done Meat Intake, and Breast Cancer Risk among Postmenopausal Women1
Anne C. Deitz2,
Wei Zheng3,
Matthew A. Leff,
Myron Gross,
Wan-Qing Wen3,
Mark A. Doll,
Gong H. Xiao,
Aaron R. Folsom and
David W. Hein4
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky 40292 [M. A. L., M. A. D., G. H. X., D. W. H.]; University of South Carolina School of Public Health and South Carolina Cancer Center, Columbia, South Carolina 29203 [W. Z., W-Q. W.]; Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis, Minnesota 55454 [M. G., A. R. F.], and Department of Pharmacology and Toxicology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58202 [A. C. D., M. A. L., M. A. D., D. W. H.]
 |
Abstract
|
|---|
Heterocyclic amines found in well-done meat require host-mediated
metabolic activation before initiating DNA mutations and tumors in
target organs. Polymorphic N-acetyltransferase-2
(NAT2) catalyzes the activation of heterocyclic amines via
O-acetylation, suggesting that NAT2
genotypes with high O-acetyltransferase activity
(rapid/intermediate acetylator phenotype) increase the risk of breast
cancer in women who consume well-done meat. To test this hypothesis,
DNA samples and information on diet and other breast cancer risk
factors were obtained from a nested case-control study of
postmenopausal women. Twenty-seven NAT2 genotypes were
determined and assigned to rapid, intermediate, or slow acetylator
groups based on published characterizations of recombinant NAT2
allozymes. NAT2 genotype alone was not associated with
breast cancer risk. A significant dose-response relationship was
observed between breast cancer risk and consumption of well-done meat
among women with the rapid/intermediate NAT2 genotype (trend test,
P = 0.003) that was not evident among women with
the slow acetylator genotype (trend test, P =
0.22). These results suggest an interaction between NAT2
genotype and meat doneness, although a test for multiplicative
interaction was not statistically significant (P =
0.06). Among women with the rapid/intermediate NAT2 genotype,
consumption of well-done meat was associated with a nearly 8-fold (odds
ratio, 7.6; 95% confidence interval, 1.150.4) elevated breast cancer
risk compared with those consuming rare or medium-done meats. These
results are consistent with a role for O-acetylation in
the activation of heterocyclic amine carcinogens and support the
hypothesis that the NAT2 acetylation polymorphism is a
breast cancer risk factor among postmenopausal women with high levels
of heterocyclic amine exposure.
 |
Introduction
|
|---|
Heterocyclic amines, such as
PhIP,5
2-amino-3-methylimidazo[4,5-f]quinoline,
and
2-amino-3,4-dimethylimidazo[4,5-f]quinoline,
which are formed when meat is cooked at high temperatures until well
done, induce mammary gland tumors in the rat (1, 2, 3)
. The
consumption of well-done meat has been associated with an elevated risk
of human breast cancer in some but not all epidemiological studies
(4)
. Heterocyclic amine carcinogens require host-mediated
metabolic activation before initiating DNA mutations that progress to
tumors in target organs (3)
.
N-Acetyltransferases catalyze the activation
(O-acetylation) of heterocyclic amine carcinogens
(5, 6, 7, 8)
and are subject to genetic polymorphism
(9)
. The NAT2 polymorphism is very common in
the human population, and individuals can be subdivided into rapid,
intermediate, and slow acetylator phenotypes (9
, 10) .
Studies investigating the relationship between NAT2 acetylator
polymorphism and breast cancer have yielded mixed results. NAT2
acetylator phenotype was not associated with breast cancer in three
studies (11, 12, 13)
. However, other studies have suggested
that the rapid NAT2 acetylator phenotype is associated with breast
cancer risk (14, 15, 16)
or advanced disease at first
presentation (17)
. Part of the inconsistency may be due to
the fact that NAT2 phenotyping assays were performed after cancer
diagnosis and/or treatment, and disease status or its sequelae may
alter acetylation rate. Furthermore, none of these studies took into
consideration the potential modifying effects of heterocyclic amine
exposure.
Recent breast cancer studies have used NAT2 genotyping
assays to assign acetylation status of study participants
(18)
. Genotype, unlike acetylator phenotype determination,
is not influenced by age, diet, disease state, environmental chemical
exposures, or concurrent drug therapy. These studies assessed three
(19, 20, 21, 22)
, four (23
, 24)
, or six
(25)
SNPs within the NAT2 coding region.
Twenty-six NAT2 alleles had been identified in human
populations when this study was initiated (9
, 26)
. The
"wild-type" allele is denoted as NAT2*4. The other 25
alleles possess a combination of one to four SNPs at 11 sites within
the 870-bp coding region. Seven SNPs result in amino acid changes
(G191A, T341C, A434C, G590A, A803G, A845C, and G857A), whereas four do
not (T111C, C282T, C481T, C759T). Based on prokaryotic recombinant
enzyme expression data, 5 NAT2 alleles (NAT2*4,
NAT2*12A, NAT2*12B, NAT2*12C, and
NAT2*13) encode proteins with a high (rapid)
O-acetylation capacity toward N-hydroxy amines,
whereas the other NAT2 alleles encode proteins with reduced
capacity (8
, 27)
. Allelic frequency varies with ethnicity
(9)
, but approximately 50% of Caucasians are
rapid/intermediate acetylators (10)
.
Many studies examining the joint effects of heterocyclic amine exposure
and enzyme polymorphisms have focused on colorectal cancer. High meat
intake and consumption of fried meats have been associated with
colorectal cancer among rapid NAT2 acetylators (28, 29, 30, 31)
.
However, many heterocyclic amines are mammary carcinogens, and, in a
recent study (32)
, we found that another
N-acetyltransferase polymorphism (NAT1) was
associated with breast cancer risk in individuals who consumed
consistently well-done meat. This study was undertaken to investigate
whether the NAT2 polymorphism is associated with breast
cancer risk and whether consumption of well-done meat modifies this
risk.
 |
Materials and Methods
|
|---|
Subjects.
Human DNA samples were obtained from the nested case-control study of
the Iowa Womens Health Study, a prospective cohort of 41,836 women,
virtually all Caucasian, aged 5569 years at the 1986 baseline survey.
Cohort members have been followed since 1986 for mortality and cancer
incidence. Detailed descriptions of this cohort study and the nested
case-control study have been published elsewhere (4
, 32, 33, 34, 35)
. Briefly, cohort members diagnosed with breast cancer
between 1992 and 1994 were classified as cases (n =
456), and a random sample of cohort members who were cancer free in
1992 were classified as controls (n = 876). Each
eligible subject (n = 1332) was asked to complete a
food frequency questionnaire about meat intake habits during the year
prior to breast cancer diagnosis or, for controls, during one of three
randomly assigned reference years (1991, 1992, or 1993). The
questionnaire assessed usual intake and preparation methods of 15
different meats. Using a series of color photographs, information on
meat doneness level was obtained for hamburger, beef steak, and bacon.
Of the 930 women who completed this supplementary questionnaire, 878
provided a buccal cell sample, and 488 also provided a blood sample
(through the mail) for genomic DNA extraction.
NAT2 Genotype Assay.
NAT2 genotype was determined using a modification of our
PCR-RFLP assay (36)
, which is designed to avoid the
pitfalls reported recently for NAT2 genotyping
(37)
. The published assay (36)
was modified
to distinguish between the 26 known human NAT2 alleles
(9)
. All NAT2 genotype assignments were blind
to case-control status. NAT2 was amplified by PCR using
50250 ng of genomic DNA in a 50-µl reaction containing 10
mM Tris-HCl (pH 8.3), 50 mM
KCl, 1.5 mM MgCl2, 0.2
mM of each deoxynucleotide triphosphate, 0.5 µg
of primer 5'-GGCTATAAGAACTCTAGGAAC-3', 0.7 µg of
5'-AAGGGTTTATTTGTTCCTTATTCTAAAT-3', and 1.25 units of Taq DNA
polymerase. The mixture was subjected to a 5-min pretreatment at
94°C, followed by 35 cycles of 1 min at 94°C, 1 min at 55°C, and
1 min at 72°C, and a 5-min extension step at 72°C.
G191A, A434C, and C481T were detected by digesting 15 µl of the
NAT2 PCR product at 37°C (>3 h) in a total volume of 30
µl with restriction enzymes MspI (10 units) and
KpnI (5 units) in NEBuffer 1 (New England Biolabs,
Beverly, MA) supplemented with 100 µg/ml BSA. G191A causes loss of a
MspI site, yielding bands of 416, 384, and 66 bp, whereas
A434C adds an additional MspI site, yielding bands of 416,
244, 93, 66, and 47 bp. C481T results in loss of the KpnI
restriction site, yielding fragments of 707, 93, and 66 bp. When
neither allele contains G191A, A434C, or C481T, 416-, 291-, 93-, and
66-bp bands result. T111C, G590A, C759T, and G857A were distinguished
after digestion of the NAT2 PCR product with TaqI
(10 units) and BamHI (10 units) at 37°C (>3 h) followed
by 65°C (>3 h) in NEBuffer BamHI (New England
Biolabs) supplemented with 100 µg/ml BSA. T111C adds a
TaqI restriction site, resulting in 252-, 226-, 170-, 98-,
80-, and 40-bp fragments. G590A and C759T delete TaqI
restriction sites, yielding bands of 396, 332, 98, and 40 bp and 332,
268, 226, and 40 bp, respectively. G857A causes loss of the
BamHI restriction site, yielding 332-, 226-, 170-, and
138-bp bands. When neither allele contains T111C, G590A, C759T, or
G857A, 332-, 226-, 170-, 98-, and 40-bp bands result. C282T and A845C
were detected by digesting PCR-amplified NAT2 with the
restriction enzymes FokI (2 units) and DraIII
(1.5 units) at 37°C (>3 h) in NEBuffer 3 (New England
Biolabs) supplemented with 100 µg/ml BSA. C282T causes loss of a
FokI site, yielding bands of 667 and 199 bp. A845C adds a
DraIII site, resulting in 429-, 238-, 153-, and 46-bp bands.
When neither allele contains C282T or A845C, 429-, 238-, and 199-bp
fragments result.
T341C and A803G were detected with nested PCR reactions. One µl
of amplified NAT2 was used as the template in a 20-µl
reaction containing 10 mM Tris-HCl (pH 8.3), 50
mM KCl, 1.5 mM
MgCl2, 0.2 mM of each
deoxynucleotide triphosphate, 220 ng of primer
5'-CACCTTCTCCTGCAGGTGACCG-3' and primer
5'-TGTCAAGCAGAAAATGCAAGGC-3' or 240 ng of primer
5'-TGAGGAGAGGTTGAAGAAGTGCT-3' and 290 ng of
5'-AAGGGTTTATTTTGTTCCTTATTCTAAAT-3', respectively, and 0.5 unit of Taq
DNA polymerase (bold indicates the nucleotide change made in
the primer sequence to generate a partial AciI restriction
site, which is underlined.) The mixture was pretreated at
94°C for 5 min, followed by 30 cycles of 30 s at 94°C, 30 s at 58°C, and 30 s at 72°C, and a 5-min extension step at
72°C.
To distinguish between C341 and T341, 20 µl of the nested PCR product
were digested at 37°C (>3 h) in a total volume of 35 µl with 5
units of AciI in NEBuffer 3 (New England Biolabs). Samples
homozygous for T341C yield bands of 121 and 20 bp instead of 141 bp.
A803G was detected after digestion of the nested PCR product with the
restriction enzyme DdeI (10 units) as described above for
AciI. When both alleles contain A803G, the 120-bp band was
cut into 97- and 23-bp fragments.
Statistical Analysis.
Individuals possessing two NAT2 alleles associated with high
acetylation activity (NAT2*4, NAT2*12A, NAT2*12B, NAT2*12C,and NAT2*13) were classified as rapid acetylators;
individuals with one of these alleles were classified as intermediate
acetylators, and individuals possessing none of these alleles were
identified as slow acetylators. ORs were used to measure the strength
of the association between exposures and cancer risk. Unconditional
logistic regression was used to control for potential confounders
assessed at the 1986 baseline survey and to derive adjusted OR and 95%
CIs. Because none of the previously identified breast cancer risk
factors confounded the association between NAT2 genotype and
breast cancer, only age was adjusted in the model. Trend tests for
dose-response relationships were performed by treating ordinal-score
variables as continuous variables in the logistic regression model.
Tests for interaction were based on the difference in the likelihood
ratios from models with and without interaction terms of genotype and
exposure. Intake levels of red meat were estimated by summing the grams
of hamburgers, cheeseburgers, beef steaks, pork chops, bacon, breakfast
sausage links and patties, other sausages, bratwurst, and hot dogs
consumed. Meat doneness levels were classified as 1, 2, or 3 for
rare/medium, well-done, and very well-done meat, respectively. A
doneness score was calculated by summing the doneness levels of
hamburger, beef steak, and bacon, the three meats for which information
on doneness was obtained. Thus, a person who reported consuming
very well-done hamburger, beef steak, and bacon received a doneness
score of 9.
 |
Results
|
|---|
NAT2 amplification was successful in 99% of DNA
samples obtained from all 488 blood samples and the 79 buccal samples
in which other genes had been successfully amplified. As shown in Table 1
, our study subjects (176 cases and 391 controls) were similar to all
eligible subjects for most demographic and breast cancer risk factors.
Ten of 26 known NAT2 alleles were identified in our
Caucasian study population (Table 2)
. The relative NAT2 allelic frequency was
NAT2*5B > NAT2*6A >
NAT2*4 > NAT2*5A > NAT2*5C
and NAT2*7B in both cases and controls. In contrast,
NAT2*13 was present in seven controls but was absent in
cases. NAT2*14 alleles were rare in both cases and controls,
as was expected in the Caucasian population. Twenty-seven different
NAT2 genotypes were determined (Table 3)
and assigned to slow, intermediate, and rapid acetylator groups based
on recombinant expression of NAT2 allozymes (8)
.
NAT2 genotype frequencies were similar between cases and
controls, although the most frequent NAT2 genotype in cases
was NAT2*4/*5B (an intermediate acetylator genotype),
whereas it was NAT2*5B/*6A (a slow acetylator genotype) in
the controls. The relative frequencies of slow, intermediate, and rapid
genotypes were similar between cases (52.9%, 41.4%, and 5.7%) and
controls (55.0%, 39.0%, and 5.9%).
View this table:
[in this window]
[in a new window]
|
Table 1 Comparison of breast cancer cases and controls by selected demographic
and risk factors among postmenopausal Iowa women
|
|
In stratified analyses (Table 4)
, meat doneness score was associated with an elevated risk of breast
cancer in a dose-dependent manner among women with rapid/intermediate
NAT2 genotype (P = 0.003) but not among
women with the slow NAT2 genotype (P =
0.22). These results suggest an interaction between NAT2
genotype and meat doneness, although a test for interaction based on a
multiplicative model was not statistically significant
(P = 0.06). Breast cancer risk appeared to increase
with level of meat intake in women with rapid/intermediate acetylator
genotype, but the trend was not significant (P = 0.11).
Meat intake level was not associated with breast cancer risk in the
slow NAT2 acetylator genotype group (trend test,
P = 0.30).
View this table:
[in this window]
[in a new window]
|
Table 4 Adjusted ORs for the association of breast cancer risk with
well-done meat intake stratified by NAT2 genotype
|
|
To enhance the stability of risk estimates for the association between
breast cancer risk and meat doneness score stratified by
NAT2 genotypes, the doneness level was collapsed into three
groups (Table 5)
. Compared with women who consumed consistently rare or medium-done
meat, breast cancer risks were elevated with increasing meat doneness,
particularly among women with the rapid/intermediate NAT2
genotype (P < 0.01). A similar pattern was found in
analyses stratified by cigarette smoking, indicating that smoking is
unlikely to explain the observed association.
View this table:
[in this window]
[in a new window]
|
Table 5 Association of well-done meat intake and breast cancer risk stratified
by NAT2 genotype and cigarette smoking
|
|
 |
Discussion
|
|---|
Metabolic activation of carcinogenic heterocyclic amines is a
multistep process catalyzed by both phase I and phase II enzymes. One
working hypothesis suggests initial N-oxidation by hepatic
CYP1A2 (38
, 39)
, followed by transport of the
N-hydroxy-heterocyclic amine to tumor target organs, where
it undergoes O-acetylation catalyzed by
N-acetyltransferase(s) that ultimately leads to DNA adducts
and mutations (9
, 40
, 41)
. This hypothesis suggests that,
compared with women with the slow NAT2 genotype, women with
the rapid/intermediate NAT2 genotype may more readily
activate heterocyclic amines present in well-done meat to reactive
metabolites that initiate DNA adducts and tumors. An alternative
hypothesis suggests that activation occurs in situ because
CYP1B1 and CYP1A1 are expressed in human mammary cells and can
metabolize PhIP to N-hydroxy-PhIP (42, 43, 44)
.
Regardless of whether N-hydroxy-PhIP is formed in the liver,
mammary gland, or both, it undergoes further activation (via
O-acetylation) by all known human NAT2 allozymes (5
, 7
, 27)
. In addition to acetyltransferases, the human mammary
gland may activate dietary mutagens by several other enzyme systems,
such as sulfotransferase(s) (45
, 46)
and prostaglandin
hydroperoxidase(s) (41)
. Additional studies investigating
the relative contribution of each of these and other enzyme systems are
needed.
NAT2 genotype was not associated with breast cancer
risk in our nested case-control study. However, we observed a
dose-dependent elevated risk among rapid/intermediate acetylators
who consumed well-done meat. Three studies reported that red meat
consumption and NAT2 genotype were not associated with
breast cancer risk (21
, 22
, 47)
. However, only one study
(47)
collected information on degree of meat doneness to
estimate the levels of heterocyclic amine exposure. The previous
studies used methods to detect only three SNPs in NAT2,
whereas our assay distinguished among 11 SNPs. Twenty-three of the
samples in our study would have been assigned an incorrect
NAT2 genotype using an assay that detects only three SNPs.
The frequency of the major NAT2 alleles in our controls was
very similar to that observed in a large Caucasian (i.e.,
German) population (48)
. However, NAT2 allelic
frequency varies with ethnicity (9)
, and this may also
account for the disparity between studies.
A study reporting that NAT2 activity was below the limit of detection
in human mammary cytosols (40)
suggests that NAT2 may not
be important for in situ activation of
N-hydroxy-heterocyclic amines. However, a role for NAT2 is
supported by studies reporting detection of NAT2 mRNA in
human mammary cells (40
, 49)
, as well as by studies that
found higher levels of NAT2 activity (50)
and
N-hydroxy-PhIP metabolic activation (51)
in
mammary cytosols from rapid NAT2 acetylator rather than
slow NAT2 acetylator congenic Syrian hamsters. In addition,
recombinant expression studies have shown that human NAT2 has a higher
selectivity for some N-hydroxy-heterocyclic amines,
including PhIP, than does NAT1 (5
, 7)
. Finally, human
mammary cells from rapid NAT2 acetylators exhibited higher levels of
heterocyclic amine DNA adducts than cells derived from slow acetylators
(52)
. Each of these findings is consistent with the
results from our study suggesting that women with the
rapid/intermediate NAT2 acetylator genotype activate
heterocyclic amines to DNA-adducting metabolites to a greater extent
than do women with the slow NAT2 acetylator genotype.
In summary, our results suggest that the NAT2 polymorphism
may be a breast cancer risk factor among women exposed to heterocyclic
amines through the consumption of well-done meat. The findings should
be interpreted with caution, due to the limitations of our study.
Although our results suggest an interaction between rapid/intermediate
NAT2 genotype and meat doneness, a test for interaction
based on a multiplicative model was not statistically significant.
Another consideration may be the low response rate for blood sample
collection and the low amplification rate of buccal DNA. There is
little reason, however, to suspect that these rates would be associated
with both case-control status and NAT2 genotype. As shown in
Table 1
, our study subjects were similar to all eligible subjects in
the associations of breast cancer risk with well-done meat intake and
in virtually all other breast cancer risk factors. The high
comparability between study participants and nonparticipants strongly
suggests that potential selection bias in our study, if any, is
unlikely to be substantial. The sample size of 174 cases and 387
controls is small, limited to Caucasians in Iowa, and heterocyclic
amine exposure was determined indirectly via dietary survey. Because
the dietary information was obtained retrospectively, problems of
differential recall between cases and controls in this cohort are
possible. Nevertheless, the results of this study, in addition to our
recent study investigating the NAT1 acetylation polymorphism
and well-done meat consumption in breast cancer risk (32)
,
provide mechanistic support for the role of well-done meat consumption
in breast cancer risk (4)
. These results, as well as
additional gene-gene-environmental interactions, need to be confirmed
in studies with a larger sample size and other ethnic populations.
 |
Acknowledgments
|
|---|
We thank Dr. R. Sinha for help in developing the meat section of
the food frequency questionnaire and for providing copies of food
photographs for assessing meat doneness level. The food frequency
questionnaire used in the study was modified from one developed by Drs.
R. Sinha and K. Anderson. We thank Drs. D. Campbell, J. Cerhan, W.
Otting, L. Kushi, K. Anderson, and T. Sellers for their contributions
to the Iowa Womens Health Study.
 |
Footnotes
|
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported in part by USPHS Grants CA34627 and
CA39742 and National Action Plan on Breast Cancer Grant OWH-284.
Portions of this work constituted partial fulfillment for a Ph.D. in
pharmacology and toxicology at the University of North Dakota by
A. C. D. 
2 Present address: Center for Clinical
Epidemiology and Biostatistics, University of Pennsylvania School of
Medicine, Philadelphia, PA 19104. 
3 Present address: Health Services Research,
Vanderbilt University Medical Center, Nashville, TN 37232. 
4 To whom requests for reprints should be
addressed, at Department of Pharmacology and Toxicology, University of
Louisville School of Medicine, Louisville, KY 40292. Phone:
(502) 852-5141; Fax: (502) 852-7868; E-mail: d.hein{at}louisville.edu 
5 The abbreviations used are: PhIP,
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; NAT2,
N-acetyltransferase-2; SNP, single-nucleotide
polymorphism; OR, odds ratio; CI, confidence interval. 
Received 12/28/99;
revised 5/17/00;
accepted 6/28/00.
 |
References
|
|---|
-
Ito N., Hasegawa R., Sano M., Tamano S., Esumi H., Takayama S., Sugimura T. A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis (Lond.), 12: 1503-1506, 1991.[Abstract/Free Full Text]
-
Ito N., Hasegawa R., Imaida K., Tamano S., Hagiwara A., Hirose M., Shirai T. Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat. Mutat. Res., 76: 107-114, 1997.
-
Snyderwine E. G. Mammary gland carcinogenesis by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats: possible mechanisms. Cancer Lett., 143: 211-215, 1999.[Medline]
-
Zheng W., Gustafson D. R., Sinha R., Cerhan J. R., Moore D., Hong C-P., Andersen K. E., Kushi L. H., Sellers T. A., Folsom A. R. Well-done meat intake and risk of breast cancer. J. Natl. Cancer Inst., 90: 1724-1729, 1998.[Abstract/Free Full Text]
-
Minchin R. F., Reeves P. T., Teitel C. H., McManus M. E., Mojarrabi B., Ilett K. F., Kadlubar F. F. N- and O-Acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem. Biophys. Res. Commun., 185: 839-844, 1992.[Medline]
-
Hein D. W., Doll M. A., Rustan T. D., Gray K., Feng Y., Ferguson R. J., Grant D. M. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis (Lond.), 14: 1633-1638, 1993.[Abstract/Free Full Text]
-
Hein D. W., Rustan T. D., Ferguson R. J., Doll M. A., Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch. Toxicol., 68: 129-133, 1994.[Medline]
-
Hein D. W., Doll M. A., Rustan T. D., Ferguson R. J. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of seven specific NAT2 nucleic acid substitutions. Cancer Res., 55: 3531-3536, 1995.[Abstract/Free Full Text]
-
Hein D. W., Doll M. A., Fretland A. J., Leff M. A., Webb S. J., Xiao G. H., Devanaboyina U-S., Nangju N. A., Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomark. Prev., 9: 29-42, 2000.[Abstract/Free Full Text]
-
Weber W. W., Hein D. W. N-Acetylation pharmacogenetics. Pharmacol. Rev., 37: 25-79, 1985.[Medline]
-
Ladero J. M., Fernandez M. J., Palmeiro R., Munoz J. J., Jara C., Lazaro C., Perez-Manga G. Hepatic acetylator polymorphism in breast cancer patients. Oncology (Basel), 44: 341-344, 1987.[Medline]
-
Webster D. J., Flook D., Jenkins J., Hutchings A., Routledge P. A. Drug acetylation in breast cancer. Br. J. Cancer, 60: 236-237, 1989.[Medline]
-
Ilett K. F., Detchon P., Ingram D. M., Castleden W. M. Acetylation phenotype is not associated with breast cancer. Cancer Res., 50: 6649-6651, 1990.[Abstract/Free Full Text]
-
Bulovskaya L. N., Krupkin R. G., Bochina T. A., Shipkova A. A., Pavlova M. V. Acetylator phenotype in patients with breast cancer. Oncology (Basel), 35: 185-188, 1978.[Medline]
-
Cartwright R. A. Epidemiological studies on N-acetylation and C-center ring oxidation in neoplasia Omen G. S. Gelboin H. V. eds. . Genetic Variability in Responses to Chemical Exposures, 16: 359-365, Cold Spring Harbor Laboratory Cold Spring Harbor, NY 1984.
-
Sardas S., Cok I., Sardas O. S., Ilhan O., Karakaya A. E. Polymorphic N-acetylation capacity in breast cancer patients. Int. J. Cancer, 46: 1138-1139, 1990.[Medline]
-
Philip P. A., Rogers H. J., Millis R. R., Rubens R. D., Cartwright R. A. Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur. J. Cancer Clin. Oncol., 23: 1701-1706, 1987.[Medline]
-
Dunning A. M., Healey C. S., Pharoah P. D. P., Teare M. D., Ponder B. A. J., Easton D. F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 8: 843-854, 1999.[Abstract/Free Full Text]
-
Ambrosone C. B., Freudenheim J. L., Graham S., Marshall J. R., Vena J. E., Brasure J. R., Michalek A. M., Laughlin R., Nemoto T., Gillenwater K. A., Shields P. G. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. J. Am. Med. Assoc., 276: 1494-1501, 1996.[Abstract/Free Full Text]
-
Hunter D. J., Hankinson S. E., Hough H., Gertig D. M., Garcia-Closas M., Spiegelman D., Manson J. E., Colditz G. A., Willett W. C., Speizer F. E., Kelsey K. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis (Lond.), 18: 2127-2132, 1997.[Abstract/Free Full Text]
-
Ambrosone C. B., Freudenheim J. L., Sinha R., Graham S., Marshall J. R., Vena J. E., Laughlin R., Nemoto T., Shields P. G. Breast cancer risk, meat consumption and N-acetyltransferase (NAT2) genetic polymorphisms. Int. J. Cancer, 75: 825-830, 1998.[Medline]
-
Gertig D. M., Hankinson S. E., Hough H., Spiegelman D., Colditz G. A., Willett W. C., Kelsey K. T., Hunter D. J. N-Acetyltransferase 2 genotypes, meat intake and breast cancer risk. Int. J. Cancer, 80: 13-17, 1999.[Medline]
-
Millikan, R. C., Pittman, G. S., Newman, B., Tse, C-K. J., Selmin, O., Rockhill, B., Savitz, D., Moorman, P. G., and Bell, D. A. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 371378, 1998.
-
Huang C-S., Chern H-D., Shen C-Y., Hsu S-M., Chang K-J. Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int. J. Cancer, 82: 175-179, 1999.[Medline]
-
Agundez J. A. G., Ladero J. M., Olivera M., Abildua R., Roman J. M., Benitez J. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. Oncology (Basel), 52: 7-11, 1995.[Medline]
-
Hein D. W., Grant D. M., Sim E. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics, 10: 291-292, 2000.[Medline]
-
Hein D. W., Doll M. A., Fretland A. J., Leff M. A. Metabolic activation of N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) by twenty-three recombinant human NAT2 allozymes. Proc. Am. Assoc. Cancer Res., 39: 455 1998.
-
Lang N. P., Butler M. A., Massengill J., Lawson M., Stotts R. C., Hauer-Jensen M., Kadlubar F. F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomark. Prev., 3: 675-682, 1994.[Abstract]
-
Roberts-Thomson I. C., Ryan P., Khoo K. K., Hart W. J., McMichael A. J., Butler R. N. Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet, 347: 1372-1374, 1996.[Medline]
-
Welfare M. R., Cooper J., Bassendine M. F., Daly A. K. Relationship between acetylator status, smoking, diet and colorectal cancer in the northeast of England. Carcinogenesis (Lond.), 18: 1351-1354, 1997.[Abstract/Free Full Text]
-
Chen J., Stampfer M. J., Hough H. L., Garcia-Closas M., Willett W. C., Hennekens C. H., Kelsey K. T., Hunter D. J. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res., 58: 3307-3311, 1998.[Abstract/Free Full Text]
-
Zheng W., Deitz A. C., Campbell D. R., Wen W-Q., Cerhan J. R., Sellers T. A., Folsom A. R., Hein D. W. N-Acetyltransferase 1 (NAT1) genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 8: 233-239, 1999.[Abstract/Free Full Text]
-
Kushi L. H., Sellers T. A., Potter J. D., Nelson C. L., Munger R. G., Kaye S. A., Folsom A. R. Dietary fat and postmenopausal breast cancer. J. Natl. Cancer Inst., 4: 1092-1099, 1992.
-
Folsom A. R., Kaye S. A., Sellers T. A., Hong C. P., Cerhan J. R., Potter J. D., Prineas R. J. Body fat distribution and 5-year risk of death in older women. J. Am. Med. Assoc., 269: 483-487, 1993.[Abstract/Free Full Text]
-
Bisgard K. M., Folsom A. R., Hong C. P., Sellers T. A. Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-u. p. Am. J. Epidemiol., 139: 990-1000, 1994.[Abstract/Free Full Text]
-
Doll M. A., Fretland A. J., Deitz A. C., Hein D. W. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal. Biochem., 231: 413-420, 1995.[Medline]
-
Cascorbi I., Roots I. Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics, 9: 123-127, 1999.[Medline]
-
Butler M. A., Iwasaki M., Guengerich F. P., Kadlubar F. F. Human cytochrome P-450PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA, 86: 7696-7700, 1989.[Abstract/Free Full Text]
-
Turesky R. J., Constable A., Richoz J., Varga N., Markovic J., Martin M. V., Guengerich F. P. Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P4501A2. Chem. Res. Toxicol., 11: 925-936, 1998.[Medline]
-
Sadrieh N., Davis C. D., Snyderwine E. G. N-Acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Cancer Res., 56: 2683-2687, 1996.[Abstract/Free Full Text]
-
Dubuisson J. G., Gaubatz J. W. Bioactivation of the proximal food mutagen 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) to DNA-binding species by human mammary gland enzymes. Nutrition, 14: 683-686, 1998.[Medline]
-
Shimada T., Hayes C. L., Yamazaki H., Amin S., Hecht S. S., Guengerich F. P., Sutter T. R. Activation of chemically diverse procarcinogens by human cytochrome P-4501B1. Cancer Res., 56: 2979-2984, 1996.[Abstract/Free Full Text]
-
Crofts F. G., Strickland P. T., Hayes C. L., Sutter T. R. Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by human cytochrome P4501B1. Carcinogenesis (Lond.), 18: 1793-1798, 1997.[Abstract/Free Full Text]
-
Crofts F. G., Sutter T. R., Strickland P. T. Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis (Lond.), 19: 1969-1973, 1998.[Abstract/Free Full Text]
-
Lewis A. J., Walle U. K., King R. S., Kadlubar F. F., Falany C. N., Walle T. Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. Carcinogenesis (Lond.), 19: 2049-2053, 1998.[Abstract/Free Full Text]
-
Yamazoe Y., Nagata K., Yoshinari K., Fujita K., Shiraga T., Iwasaki K. Sulfotransferase catalyzing sulfation of heterocyclic amines. Cancer Lett., 143: 103-107, 1999.[Medline]
-
Delfino R. J., Sinha R., Smith C., West J., White E., Lin H. J., Liao S-Y., Gim J. S. Y., Ma H. L., Butler J., Anton-Culver H. Breast cancer, heterocyclic aromatic amines from meat and N-acetyltransferase 2 genotype. Carcinogenesis (Lond.), 21: 607-615, 2000.[Abstract/Free Full Text]
-
Cascorbi I., Brockmoller J., Mrozikiewicz P. M., Muller A., Roots I. Arylamine N-acetyltransferase activity in man. Drug Metab. Rev., 31: 489-502, 1999.[Medline]
-
Debiec-Rychter M., Land S. J., King C. M. Histological localization of acetyltransferases in human tissue. Cancer Lett., 143: 99-102, 1999.[Medline]
-
Deitz A. C., Doll M. A., Hein D. W. Acetylation polymorphism in mammary tissue from Syrian hamsters congenic at the NAT2 locus. Proc. Am. Assoc. Cancer Res., 37: 130-131, 1996.
-
Fretland, A. J., Devanaboyina, U. S., Nangju, N. A., Leff, M. A., Xiao, G. H., Webb, S. J., Doll, M. A., and Hein, D. W. DNA adduct levels and absence of tumors in female rapid and slow acetylator congenic hamsters administered the rat mammary carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine. J. Biochem. Mol. Toxicol., 15: in press, 2001.
-
Stone E. M., Williams J. A., Grover P. L., Gusterson B. A., Phillips D. H. Interindividual variation in the metabolic activation of heterocyclic amines and their N-hydroxy derivatives in primary cultures of human mammary epithelial cells. Carcinogenesis (Lond.), 19: 873-879, 1998.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
F. A. Jefferson, G. H. Xiao, and D. W. Hein
4-Aminobiphenyl Downregulation of NAT2 Acetylator Genotype-Dependent N- and O-acetylation of Aromatic and Heterocyclic Amine Carcinogens in Primary Mammary Epithelial Cell Cultures from Rapid and Slow Acetylator Rats
Toxicol. Sci.,
January 1, 2009;
107(1):
293 - 297.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zang, M. A. Doll, S. Zhao, J. C. States, and D. W. Hein
Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2
Carcinogenesis,
August 1, 2007;
28(8):
1665 - 1671.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Ochs-Balcom, G. Wiesner, and R. C. Elston
A Meta-Analysis of the Association of N-Acetyltransferase 2 Gene (NAT2) Variants with Breast Cancer
Am. J. Epidemiol.,
August 1, 2007;
166(3):
246 - 254.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Bendaly, S. Zhao, J. R. Neale, K. J. Metry, M. A. Doll, J. C. States, W. M. Pierce Jr., and D. W. Hein
2-Amino-3,8-Dimethylimidazo-[4,5-f]Quinoxaline-Induced DNA Adduct Formation and Mutagenesis in DNA Repair-Deficient Chinese Hamster Ovary Cells Expressing Human Cytochrome P4501A1 and Rapid or Slow Acetylator N-Acetyltransferase 2
Cancer Epidemiol. Biomarkers Prev.,
July 1, 2007;
16(7):
1503 - 1509.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhu, D. W. Hein, M. A. Doll, K. K. Reynolds, N. Abudu, R. Valdes Jr, and M. W. Linder
Simultaneous Determination of 7 N-Acetyltransferase-2 Single-Nucleotide Variations by Allele-Specific Primer Extension Assay
Clin. Chem.,
June 1, 2006;
52(6):
1033 - 1039.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Deitz, N. Rothman, T. R. Rebbeck, R. B. Hayes, W.-H. Chow, W. Zheng, D. W. Hein, and M. Garcia-Closas
Impact of Misclassification in Genotype-Exposure Interaction Studies: Example of N-Acetyltransferase 2 (NAT2), Smoking, and Bladder Cancer
Cancer Epidemiol. Biomarkers Prev.,
September 1, 2004;
13(9):
1543 - 1546.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Kocabas, S. Sardas, S. Cholerton, A. K. Daly, and A. E. Karakaya
N-Acetyltransferase (NAT2) Polymorphism and Breast Cancer Susceptibility: A Lack of Association in a Case-Control Study of Turkish Population
International Journal of Toxicology,
January 1, 2004;
23(1):
25 - 31.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Stripp, K. Overvad, J. Christensen, B. L. Thomsen, A. Olsen, S. Moller, and A. Tjonneland
Fish Intake Is Positively Associated with Breast Cancer Incidence Rate
J. Nutr.,
November 1, 2003;
133(11):
3664 - 3669.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Zhu, P. Chang, M. L. Bondy, A. A. Sahin, S. E. Singletary, S. Takahashi, T. Shirai, and D. Li
Detection of 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]-Pyridine-DNA Adducts in Normal Breast Tissues and Risk of Breast Cancer
Cancer Epidemiol. Biomarkers Prev.,
September 1, 2003;
12(9):
830 - 837.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Lan, N. Rothman, W.-H. Chow, J. Lissowska, M. A. Doll, G. H. Xiao, W. Zatonski, and D. W. Hein
No Apparent Association between NAT1 and NAT2 Genotypes and Risk of Stomach Cancer
Cancer Epidemiol. Biomarkers Prev.,
April 1, 2003;
12(4):
384 - 386.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Chang-Claude, S. Kropp, B. Jager, H. Bartsch, and A. Risch
Differential Effect of NAT2 on the Association between Active and Passive Smoke Exposure and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev.,
August 1, 2002;
11(8):
698 - 704.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility
J. Med. Genet.,
April 1, 2002;
39(4):
225 - 242.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Le Marchand, J. H. Hankin, L. R. Wilkens, L. M. Pierce, A. Franke, L. N. Kolonel, A. Seifried, L. J. Custer, W. Chang, A. Lum-Jones, et al.
Combined Effects of Well-done Red Meat, Smoking, and Rapid N-Acetyltransferase 2 and CYP1A2 Phenotypes in Increasing Colorectal Cancer Risk
Cancer Epidemiol. Biomarkers Prev.,
December 1, 2001;
10(12):
1259 - 1266.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. W. Hein, C. A. McQueen, D. M. Grant, G. H. Goodfellow, F. F. Kadlubar, and W. W. Weber
Pharmacogenetics of the Arylamine N-Acetyltransferases: A Symposium in Honor of Wendell W. Weber
Drug Metab. Dispos.,
April 13, 2001;
28(12):
1425 - 1432.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
W. Zheng, D. Xie, J. R. Cerhan, T. A. Sellers, W. Wen, and A. R. Folsom
Sulfotransferase 1A1 Polymorphism, Endogenous Estrogen Exposure, Well-done Meat Intake, and Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev.,
February 1, 2001;
10(2):
89 - 94.
[Abstract]
[Full Text]
|
 |
|